|
Nov 11
|
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
|
|
Aug 31
|
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?
|
|
Aug 6
|
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
|
|
May 3
|
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
|
|
Apr 29
|
BeyondSpring Files 2023 Annual Report on Form 20-F
|
|
Apr 29
|
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
|
|
Mar 25
|
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
|
|
Mar 6
|
Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded
|
|
Jan 10
|
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
|